A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer Meeting Abstract


Authors: Girda, E.; Makker, V.; Marth, C.; Van Gorp, T.; Mirza, M.; Shapira-Frommer, R.; Suttner, L.; Groisberg, R.; Jin, F.; O'Malley, D.
Abstract Title: A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer
Meeting Title: Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer
Journal Title: Gynecologic Oncology
Volume: 190
Issue: Suppl. 1
Meeting Dates: 2024 Mar 15-18
Meeting Location: San Deigo, CA
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2024-11-01
Start Page: S293
End Page: S294
Language: English
ACCESSION: WOS:001330731400426
DOI: 10.1016/j.ygyno.2024.07.438
PROVIDER: wos
Notes: Meeting Abstract: 2140 [TIP] -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Vicky Makker
    265 Makker